FDA Approves Viridian’s Thyroid Eye Disease Drug, Competitor to a Blockbuster Amgen Med
Viridian Therapeutics’ Lumvoa is approved for treating both the chronic and active phases of thyroid…
FDA Approves Viridian’s Thyroid Eye Disease Drug, Competitor to a Blockbuster Amgen Med
Viridian Therapeutics’ Lumvoa is approved for treating both the chronic and active phases of thyroid eye disease. This drug will offer patients an alternative to Tepezza, an Amgen drug that had been the only approved therapy for this inflammatory eye disorder. The post FDA Approves Viridian’s Thyroid Eye Disease Drug, Competitor to a Blockbuster Amgen…
CMS Recalculates Star Ratings — Again
CMS is recalculating some 2026 Medicare Advantage Star Ratings after a court ruled it improperly calculated Clover Health’s rating, a decision that could boost payments for a small number of insurers. The post CMS Recalculates Star Ratings — Again appeared first on MedCity News.
A Bridge to Nowhere? Medicare’s GLP-1 Coverage Expansion Requires A More Holistic Approach To Weight Management
For seniors, the change in policy will dramatically expand access to a revolutionary medication. But there are also significant risks. The post A Bridge to Nowhere? Medicare’s GLP-1 Coverage Expansion Requires A More Holistic Approach To Weight Management appeared first on MedCity News.
Healthcare’s Most Avoided Question: “How Much Exactly Do You Need, and What Will America Get in Return?”
Before policymakers, employers, insurers, or taxpayers commit ever-larger sums to the system, an uncomfortable question deserves attention: How much additional capacity does healthcare actually need and what measurable outcomes should society expect in return? The post Healthcare’s Most Avoided Question: “How Much Exactly Do You Need, and What Will America Get in Return?” appeared first…
3 Traps Health Systems Fall Into When Trying to Improve Their Culture
Cultivating a positive culture is a priority for hospital leaders, but many are making avoidable mistakes. Myra Gregorian, Seattle Children’s chief people and transformation officer, outlined some of these common blunders — such as not involving frontline staff in decision making and assuming that simple communication methods are sufficient. The post 3 Traps Health Systems…
The Terminology Gap Undermining Cervical Cancer Screening Guidelines
While the Pap identifies the cell changes, the HPV test determines the root cause before those changes even happen. Both tests have saved lives. But they are not interchangeable, and treating them as such puts the patient at risk. The post The Terminology Gap Undermining Cervical Cancer Screening Guidelines appeared first on MedCity News.
Reporters Talk Through FDA Sunscreen Move and Closure of Rural Dialysis Clinics
KFF Health News freelance contributor Michael Scaturro discussed the FDA’s new approval of a sunscreen chemical on Science Friday on June 19. Click here to hear Scaturro on Science Friday. Read Scaturro’s “FDA’s Greenlight of Old Chemical Offers Chance To Restore Faith in Sunscreen.” KFF Health News South Dakota correspondent Arielle Zionts discussed the closure…
Pharmaceutical Manufacturer response to Most Favored Nation (MFN): Delay, Hide or Confuse?
Today I attended the very interesting ISPOR Health Policy Leadership Exchange (HPLE) in Washington DC on the topic of Most Favored Nation (MFN). There were a number of important points made and I’ll summarize a few of them. First, US drug prices are much higher than in other OECD countries. An ASPE report from 2024…
EMA: Amgen, Vifor Inflammatory Drug’s Benefits No Longer Outweigh Risks
A European Medicines Agency committee now recommends withdrawing marketing authorization for Tavneos, an Amgen drug marketed in Europe by a CSL Limited subsidiary. Meanwhile, an FDA proposal to withdraw the drug from the U.S. market is set to go to a hearing. The post EMA: Amgen, Vifor Inflammatory Drug’s Benefits No Longer Outweigh Risks appeared…
New Bill Led by Democrats Aims to Cap Medicare Out-of-Pocket Costs
The Medicare Cost Cap Act seeks to create a $5,000 cap on out-of-pocket costs for traditional Medicare beneficiaries. The post New Bill Led by Democrats Aims to Cap Medicare Out-of-Pocket Costs appeared first on MedCity News.
